It's the monetary policy equivalent of Sherlock Holmes's "curious incident" of the dog that didn't bark in the night
The fast-food Tex-Mex chain’s breakfast campaign recalls a series of Jack in the Box ads from more than a decade ago
His chief plaint seems to be that Staples outposts wouldn't be staffed by union members
Venture capital fundraising is on the rise in the first quarter, while stocks from Facebook, Twitter, and others have dropped in recent weeks
After five years of trying to keep banks from all failing together, now we have to worry about asset managers?
Even Thomas Edison and Leonardo da Vinci benefited from collaboration
Kevin Costner's latest sports flick, Draft Day, suggests that the front office is where the real action happens
He's trying to "improve his résumé," says his lawyer
Alabama Republican Jeff Sessions wants the SBA to share more data on loan defaults that put taxpayer money at risk
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."